SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : STEM -- StemCells, Inc.
STEM 17.01+3.0%12:27 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stanley L. Freedman who wrote (238)4/28/1999 7:19:00 PM
From: Mike McFarland  Read Replies (1) of 805
 
No kidding (what direction) I thought
everything pretty much depended on the
Astra pain trials at this point...unless
of course things have got to the stage
where they're willing to sell out.

Of course, at book value, there seems to be
no downside risk in the short term. And these
directors are usually paid well, so great--with
the savings they can hire another research
scientist...maybe several.

The current Phase II pain trial completed patient
enrollment in March 1999, with efficacy data from the
trial expected by the third quarter of 1999. Astra has
agreed to fund the first and second quarters of 1999 at
the rate of $2.5 million per quarter. Funding for the
second half of 1999 is contingent upon, among other
factors, the results of the current Phase II trial.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News